1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 3: 
Angiographic outcomes assessed by core lab: immediate, 3 months, and 1 year
Small <10 mmLarge 10–24 mmGiant >25 mm
Postembolization occlusion rates
n = 20 (%)n = 60 (%)n = 19 (%)
 Complete (100%)15 (75)33 (55)19 (47)
 Subtotal (90–99%)5 (25)26 (43)19 (47)
 Incomplete (<90%)—1 (2)1 (5)
3–6 month follow-up occlusion rates
n = 15 (%)n = 51 (%)n = 15 (%)
 Complete (100%)13 (86.7)31 (61)8 (53)
 Subtotal (90–99%)1 (6.7)12 (23)4 (27)
 Incomplete (<90%)1 (6.7)7 (14)2 (13)
 Not determinable1 (2)1 (7)
12-month follow-up occlusion rates
After re-treatment, when applicable
n = 14 (%)n = 39 (%)n = 14 (%)
 Complete (100%)13 (93)30 (77)8 (57)
 Subtotal (90–99%)05 (13)2 (14)
 Incomplete (<90%)1 (7)2 (5)2 (14)
 Not determinable2 (5)2 (14)